Target-26

Target-26 is a preclinical-stage drug candidate developed by Cerevance for the treatment of Alzheimer's disease. The program was identified using Cerevance's proprietary NETSseq platform, which utilizes deep-sequencing of cell-type-specific nuclei from human brain tissue to identify novel therapeutic targets that are selectively expressed in vulnerable or resilient cell populations. Target-26 is characterized as a potential disease-modifying therapy. While the specific biological target remains proprietary and undisclosed, the program is part of Cerevance's broader effort to develop orally bioavailable small molecules that address neurodegenerative diseases by targeting specific neuronal or glial populations identified through their human-centric discovery engine.